Robert W. Ross

16.2k citations
61 papers · 11.1k indexed · 1 hit paper · h-index 27

Robert W. Ross

59 papers receiving 10.8k citations

Hit Papers

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin...8.4k20042026201120182.5k5.0k7.5k

Peers

Robert W. Ross
Comparison fields: 5 of 137
  • Oncology 6.1k
  • Hepatology 1.7k
  • Cancer Research 1.9k
  • Pulmonary and Respiratory Medicine 3.5k
  • Molecular Biology 3.9k
Replace W. Heim with:
W. Heim United States
Gwen Fyfe United States
Ari David Baron United States
Lee S. Rosen United States
Yves Humblet Belgium
Howard S. Höchster United States
Gabriella Fontanini Italy
J. Wanders Netherlands
Michael S. O’Reilly United States
David Khayat France
Robert W. Ross relative to W. Heim United States W. Heim's profile →
Citations per field
00.5×1.5×
W. Heim · 1×
Citations per year

Countries citing papers authored by Robert W. Ross

Since Specialization
Citations

This map shows the geographic impact of Robert W. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Ross more than expected).

Fields of papers citing papers by Robert W. Ross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Ross. The network helps show where Robert W. Ross may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Robert W. Ross, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert W. Ross Line = papers co-authored together Robert W. Ross links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 202014
2 201430
3 201247
4 201159
5 20116
6 201093
7 201017
8 2009103
9 200888
10 200890
11 200836
12 200899
13
A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC).
20077
14 200776
15 200785
16 20064
17 200581
18 200422
19 20024
20 200052

About Robert W. Ross

Robert W. Ross is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Parasitology, having authored 61 papers that have together received 11.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (12 papers), Bladder and Urothelial Cancer Treatments (9 papers), Cancer Treatment and Pharmacology (5 papers), Renal cell carcinoma treatment (4 papers), Hormonal and reproductive studies (4 papers), Hedgehog Signaling Pathway Studies (4 papers) and Molecular Biology Techniques and Applications (4 papers). The work is most often cited by research in Oncology (6.1k citations), Hepatology (1.7k citations), Cancer Research (1.9k citations), Pulmonary and Respiratory Medicine (3.5k citations) and Molecular Biology (3.9k citations). Robert W. Ross has collaborated with scholars based in United States, Greece and Spain. Frequent co-authors include Thomas H. Cartwright, Herbert I. Hurwitz, Ari David Baron, Fairooz F. Kabbinavar, Eric Holmgren, Gwen Fyfe, Louis Fehrenbacher, W. Heim, John D. Hainsworth and Napoleone Ferrara. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Clinical Cancer Research, British Journal of Urology and Clinical Genitourinary Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026